Cortellis Competitive Intelligence

Discover the undiscovered with Cortellis Competitive Intelligence

Highlights

  • Intuitive web-based interface
  • Expert analytics & visualizations
  • Export & reporting tools

Intended for

  • Business Development Professional
  • Competitive Intelligence Professional
  • Research & Development Professionals

Description

Thomson Reuters Cortellis™ Competitive Intelligence combines the same premier information used by the world's leading pharmaceutical companies from products such as Thomson Reuters Pharma™ and Thomson Reuters Partnering™ (formerly IDDB). Featuring daily updates and timely drug pipeline information expertly uncovered and integrated from a variety of sources and global meetings coverage, you'll always be on top of the latest developments. Whether you're putting together a pipeline analysis, or developing a comprehensive competitive intelligence study, Cortellis Competitive Intelligence can get you to the critical information you need, faster.

To find out more, visit us on the Cortellis website.

Features

  • An easy and intuitive web-based interface – find the exact data you want, whenever you want
  • Speed decision making – with easy-to-use analytics and visualizations to quickly interrogate data
  • Share and present your findings – with agile export and reporting tools
  • Drug profiles providing a history of the drug: companies involved in drug discovery and development, patent protection, chemical structure, target / MoA, indications in development.
  • Details on discovery-stage, and pre-clinical data & clinical development, including ongoing and completed clinical trials
  • Company profiles: descriptions of your competitors' areas of focus, financial state, drug pipelines, and listings of significant partnerships and drug licensing deals
  • Deals: including financial terms, milestones, timelines and relevant drugs and patents associated with each deal
  • Patents: expirations, infringements, and exclusivity
  • Forecasts: on similar drugs provide insight and a starting point for forecasting sales potential

Benefits

  • Identify market gaps early
  • Look for potential partners
  • Assess comparable deals
  • Discover targets with active patenting activity
  • Research competitor pipelines
  • Review a company’s strategic portfolio

Display Settings:

The application is best viewed at a monitor resolution of 1024 by 768 pixels or higher, and at 256 colors or more (High Color or True Color recommended).

Browser Requirements:

The supported environment for Cortellis is Microsoft® Internet Explorer version 8.0 with the Windows 7 operating environment. We also test Cortellis within the following environments:
  • Internet Explorer 9 Windows 7
  • Internet Explorer 10 Windows 7
  • Chrome 30.0.1599.66 Windows 7
  • Firefox 24  Windows 7
  • iPad with OS 6.x OS 6.x

Internet Options:

Exported results/reports are downloaded into a separate browser window. You must therefore ensure you temporarily disable/turn off any pop-up blockers on your computer, since the content will not export correctly when a pop-up blocker is active.

Javascript:

The application uses JavaScript for defining menus and navigation, opening new windows and for the processing of requests. You must therefore enable the JavaScript option within your web browser to use the application successfully.

Cookies:

In order to utilize all of the features available in the application, we recommend updating your Internet settings to enable or allow cookies for this website.

Adobe Reader:

The application provides some exports in PDF format, to enable easy viewing and printing. You must therefore ensure that Adobe Reader is installed on your machine to export successfully. Adobe Reader is available for download free of charge, from the Adobe website.

Case Study

Gaining a Full Picture of the Competitive Landscape for Evidence-based Decisions

aTyr seeks to develop innovative therapeutics to address the unmet needs of patients by developing a novel class of biologic drugs based on a recently discovered set of human proteins.

Case Study

Painting the Competitive Landscape: A Single Source for a Complete Picture

Nabriva Therapeutics is a small biotechnology company based in Austria, successfully spun off from Novartis in 2006. They have been working in the field of antibiotics for more than 12 years and specialize in R&D of antibacterial treatments of resistant infections.

Case Study

Competitive Timelines: How Cortellis Competitive Intelligence is Accelerating Research at a US Preclinical Biotech Company

aTyr is a re-clinical biotech company based in San Diego, California, founded based on innovative discoveries made at the Scripps Research Institute in La Jolla, California.

Case Study

Navigating the Pipeline

The Leukemia & Lymphoma society® (LLs) is the world’s largest voluntary health agency dedicated to blood cancer. Their mission is to cure leukemia, lymphoma, hodgkin’s disease and myeloma, and improve the quality of life of patients and their families.

Cortellis Broker Research


Access the world's most comprehensive Broker Research reports
Written by 1,600 contributing brokers, 30 of which are unique to Thomson Reuters, Broker Research offers authoritative analyses of companies, industries, drugs and global markets. Market-leading broker research, together with the broad and complete coverage of life sciences companies and drug development on Cortellis, provides the most comprehensive intelligence. Allowing you to make the right decisions, with confidence.

Cortellis Event Transcripts


Discover what your peers are saying and read the full-text transcripts of corporate conference calls
Discover what your peers are saying on their conference calls and read the full-text transcripts of corporate conference calls, including the Q&A.
Hear first-hand the important information company officials impart to investors, analysts, the media, and scientists and the responses to their questions.

  • Alnylam selects ALN-AGT as preclinical candidate for hypertensive disorders of pregnancy

    33m 0 0

  • Reduced bone resorption with less effect on bone formation with MK0674 versus alendronate and denosumab. Preclinical research at #ASBMR14

    13h 1 0

  • siRNA as potential therapy for mutated CLCN7-related autosomal dominant osteopetrosis type 2: candidates patented, as shown at #ASBMR14

    13h 4 0

  • Visit Twitter

Download Fact Sheet

Fact Sheets